1. Comparison of Sequence Analysis and the INNO-LiPA HBV DR Line Probe Assay for Detection of Lamivudine-Resistant Hepatitis B Virus Strains in Patients under Various Clinical Conditions
2. Ahn, S. H., Y. N. Park, J. Y. Park, H. Y. Chang, J. M. Lee, J. E. Shin, K. H. Han, C. Park, Y. M. Moon, and C. Y. Chon. 2005. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol.42:188-194.
3. Akuta, N., F. Suzuki, M. Kobayashi, A. Tsubota, Y. Suzuki, T. Hosaka, T. Someya, M. Kobayashi, S. Saitoh, Y. Arase, K. Ikeda, and H. Kumada. 2003. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol.38:315-321.
4. Alberti, A. 2003. Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? Hepatology38:18-20.
5. Allain, J. P. 2004. Occult hepatitis B virus infection: implications in transfusion. Vox Sang.86:83-91.